Breaking Finance News

Esperion Therapeutics (NASDAQ:ESPR) has been upgraded from Underperform to Neutral in a statement by Credit Suisse earlier today.

Boasting a price of $23.67, Esperion Therapeutics (NASDAQ:ESPR) traded 52.64% higher on the day. With the last stock price close up 140.83% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. The company has recorded a 50-day moving average of $23.80 and a 200-day moving average of $15.00. 9,355,593 shares of the stock traded hands, up from an average trading volume of 931,170

Credit Suisse has upgraded Esperion Therapeutics (NASDAQ:ESPR) from Underperform to Neutral in a statement released on 3/20/2017.

On 2/28/2017, Citigroup Inc released a statement for Esperion Therapeutics (NASDAQ:ESPR) bumped up the target price from $14.00 to $39.00 that suggested an upside of 0.25%.

See Chart Below

Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $37.16 The company’s market cap is currently $0.

In addition to Credit Suisse reporting its stock price target, a total of 12 brokers have issued a report on the company. The average stock price target is $32.67 with 3 brokers rating the stock a strong buy, 8 brokers rating the stock a buy, 2 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.